511 related articles for article (PubMed ID: 30048343)
41. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience.
Burstein DS; Maude S; Grupp S; Griffis H; Rossano J; Lin K
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1590-1595. PubMed ID: 29772353
[TBL] [Abstract][Full Text] [Related]
42. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
43. The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
Annesley CE; Summers C; Ceppi F; Gardner RA
Clin Pharmacol Ther; 2018 Apr; 103(4):591-598. PubMed ID: 29171004
[TBL] [Abstract][Full Text] [Related]
44. Advances in CAR T Therapy for Hematologic Malignancies.
Freyer CW; Porter DL
Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
[TBL] [Abstract][Full Text] [Related]
45. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
[TBL] [Abstract][Full Text] [Related]
46. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
47. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
48. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
Belin C; Devic P; Ayrignac X; Dos Santos A; Paix A; Sirven-Villaros L; Simard C; Lamure S; Gastinne T; Ursu R; Berger C; Platon L; Tessoulin B; Azoulay E; Wallet F; Thieblemont C; Bachy E; Cartron G; Laplaud DA; Carpentier AF
Sci Rep; 2020 Nov; 10(1):18997. PubMed ID: 33149178
[TBL] [Abstract][Full Text] [Related]
49. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
[TBL] [Abstract][Full Text] [Related]
50. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
51. Cytokine Release Syndrome: Inpatient Care for Side Effects of CAR T-Cell Therapy
.
Smith L; Venella K
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):29-34. PubMed ID: 28315560
[TBL] [Abstract][Full Text] [Related]
52. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy.
Luo H; Wang N; Huang L; Zhou X; Jin J; Li C; Wang D; Xu B; Xu J; Jiang L; Wang J; Cao Y; Xiao Y; Zhang Q; Mao X; Liu S; Chen L; Xiao M; Zhou J
J Immunother Cancer; 2019 Oct; 7(1):271. PubMed ID: 31640816
[TBL] [Abstract][Full Text] [Related]
54. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.
Gust J; Taraseviciute A; Turtle CJ
CNS Drugs; 2018 Dec; 32(12):1091-1101. PubMed ID: 30387077
[TBL] [Abstract][Full Text] [Related]
55. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.
Fortin Ensign SP; Gaulin C; Hrachova M; Ruff M; Harahsheh E; Vicenti K; Castro J; Munoz J; Rosenthal A; Mrugala MM
Curr Treat Options Oncol; 2022 Dec; 23(12):1845-1860. PubMed ID: 36525238
[TBL] [Abstract][Full Text] [Related]
56. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
57. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
58. From bench to bedside: the history and progress of CAR T cell therapy.
Mitra A; Barua A; Huang L; Ganguly S; Feng Q; He B
Front Immunol; 2023; 14():1188049. PubMed ID: 37256141
[TBL] [Abstract][Full Text] [Related]
59. Cytokines in CAR T Cell-Associated Neurotoxicity.
Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
Front Immunol; 2020; 11():577027. PubMed ID: 33391257
[TBL] [Abstract][Full Text] [Related]
60. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]